Zynerba Pharmaceuticals Achieves Target Enrollment In Exploratory Phase 2 Trial Of ZYN002 In Fragile X Syndrome

Top-line data from this study remains on track to report in September 2017

Devon, PA (GLOBE NEWSWIRE) – Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments, today announced that it has met its enrollment target of 16 patients in its Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in children with Fragile X syndrome (FXS). ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery, and was awarded orphan drug designation by the U.S. Food and Drug Administration for the treatment for FXS.

Patients between the ages of 6 and 17 years with Fragile X syndrome have been enrolled in the exploratory FAB-C trial, which is designed to evaluate the safety and efficacy of ZYN002 CBD gel

... read more at: https://www.clinicalleader.com/doc/zynerba-pharmaceuticals-achieves-target-exploratory-phase-syndrome-0001